Nilsine Partners LLC Raises Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Nilsine Partners LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,489 shares of the life sciences company’s stock after purchasing an additional 213 shares during the period. Nilsine Partners LLC’s holdings in Illumina were worth $466,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in ILMN. Versant Capital Management Inc boosted its position in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the period. TD Private Client Wealth LLC boosted its holdings in Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares during the period. Massmutual Trust Co. FSB ADV grew its position in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares in the last quarter. Private Trust Co. NA raised its stake in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares during the period. Finally, Focused Wealth Management Inc acquired a new position in shares of Illumina during the third quarter worth $63,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Down 1.4 %

Illumina stock opened at $131.72 on Thursday. The firm has a market capitalization of $20.89 billion, a P/E ratio of -13.22 and a beta of 1.11. The company has a 50-day simple moving average of $139.05 and a 200-day simple moving average of $135.07. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina’s revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.33 earnings per share. As a group, equities analysts expect that Illumina, Inc. will post 4.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several analyst reports. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. TD Cowen raised their price objective on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Barclays upped their target price on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. raised their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.